Summary Four patients underwent intraoperative photodynamic therapy after surgery with meso-tetra-(hydroxyphenyl)-chlorin (mTHPC-PDT) for diffuse malignant mesothelioma. Preliminary procedures were performed in two patients in order to establish the efficacy of mTHPC-PDT and to optimise its tumoricidal effect. The (Faber, 1988) . Improved local control does require additional measures, but the disease responds poorly to radio-and chemotherapy (Lerner et al., 1983) . As photodynamic therapy (PDT) has been reported to be effective in human mesothelioma xenografts (Feins et al., 1990) , it might allow for an appropriate 'clean-up' of the thoracic cavity after surgery. For clinical purposes, the currently used sensitisers for PDT are haematoporphyrin derivatives (HpD) and dihaematoporphyrin ether (DHE) . However, PDT with meso-tetra-(hydroxyphenyl)-chlorin (mTHPC) was superior to DHE-PDT with respect to antitumour activity and tissue selectivity in rodents without causing significant toxicity (Berenbaum, 1989) . mTHPC might therefore be better fitted to large surface PDT as required for diffuse malignant mesothelioma treatment. A pilot study was done to evaluate mTHPC-PDT for diffuse malignant mesothelioma with respect to its antitumour activity and the feasibility of a combined modality approach under clinical conditions.
Diffuse malignant mesothelioma spreads on pleural and peritoneal surfaces with invasion of the underlying structures, first of all of the diaphragm. There is no cure at present. Patients succumb in general from relentless local progression of the disease regardless of the treatment performed and not from distant metastatic spread, indicating that local control is not effective even if extended resections have been performed (Faber, 1988) . Improved local control does require additional measures, but the disease responds poorly to radio-and chemotherapy (Lerner et al., 1983) . As photodynamic therapy (PDT) has been reported to be effective in human mesothelioma xenografts (Feins et al., 1990) , it might allow for an appropriate 'clean-up' of the thoracic cavity after surgery. For clinical purposes, the currently used sensitisers for PDT are haematoporphyrin derivatives (HpD) and dihaematoporphyrin ether (DHE) . However, PDT with meso-tetra-(hydroxyphenyl)-chlorin (mTHPC) was superior to DHE-PDT with respect to antitumour activity and tissue selectivity in rodents without causing significant toxicity (Berenbaum, 1989) . mTHPC might therefore be better fitted to large surface PDT as required for diffuse malignant mesothelioma treatment. A pilot study was done to evaluate mTHPC-PDT for diffuse malignant mesothelioma with respect to its antitumour activity and the feasibility of a combined modality approach under clinical conditions. Patients tumour. The diaphragm was debulked yet preserved in all four patients in order to keep intact this natural barrier to the peritoneal cavity. The pericardium was removed in patient 1 and 2, preserved in patient 3 and partially removed and replaced by a vicryl mesh in patient 4. After the resection, the light was delivered through the open chest wound, with a dose of 10 J cm2 to the diaphragm and the costophrenic sulcus and of 5 J cm-2 to the remaining cavity (including the lung in patients 3 and 4). The diameters of the light spots varied from 5 to 12 cm, according to the geometry of the area treated. To reduce additional loss of energy and divergence of the laser beam, the light was delivered through a bare fibre rather than a lens. The spots were therefore overlapped to prevent unequal light distribution by the bare fibre. The maximal laser power output at the end of the fibre was 1.5 Watt in patient 1, 2 and 3. Patient 4 was treated by a new high power laser system, allowing for 4 Watt at the end of the fibre at 650 nm. The heart was shielded from direct irradiance by a moist towel in patients 1 and 2. mTHPC concentrations were measured in the tumour and in normal tissues 48 h after mTHPC-administration.
Results
Preliminary PDT Tumour response to mTHPC-PCT 0.075mgkg-' mTHPC and 10 Joules cm-2 delivered after 24 h resulted in frank necrosis of approximately 50% of tumour on semi-serial sections investigated from treated areas (diameter of biopsy b c specimen: 10 mm). The histologic pattern of necrosis was consistent with tumour infarction. Tumour vessels showed a fibrinoid necrosis of the vessel wall and thrombosis. The tumour necrosis extended from the vascular watershed towards the vessels whereas the remaining 50% of tissue around the vessels appeared edematous and possibly viable (perivascular sparing, Figure lb) . Specimens taken from untreated tumour areas served as controls and showed no spontaneous tumour necrosis (Figure la) . 0.15 mg mTHPC kg-' activated after 24 h with 10 Joules cm 2 resulted in a 50% to 80% infarction related tumour destruction. However, balloonated basophilic tumour cells of questionable viability and prominent interstitial edema were observed with 0.15 mg mTHPC kg ' and 2 Joules cm2 delivered after 24 h (Figure 2b) . No spontaneous tumour necrosis was found in biopsy specimens from adjacent but untreated tumour areas (Figure 2a) respectively. Nine days after administration, mTHPC was still detectable in the plasma (4 tLg 100 ml-'). No mTHPC or metabolites were identified in urine samples at any time.
Intraoperative PDTfollowing surgery An additional 2 h were required for PDT of the thoracic cavity in patients 1, 2 and 3 after completion of the surgical tumour resection. Appropriate exposure of the costophrenic sulcus was obtained by manual retraction of the diaphragm. Difficulties were encountered in ensuring equal and sufficient light distribution to the anterior chest wall in these three patients and to the entire surface of the collapsed lung in patient 3. Patient 4 was treated with a new high power laser system and the overall PDT treatment time was reduced to 50 min. Appropriate light delivery to the costophrenic sulcus, the anterior chest wall and to the remnant lung was much easier in this patient due to the markedly reduced treatment time.
Postoperative course Loss of appetite, fluid retention (up to 8 kg), hypoproteinemia (50.4 ± 7 g 1'-l) and more severe chest pain than anticipated from the surgical procedure per se were specific side effects following this combined approach. Serum cre-ktinine values and urine output were normal throughout.
SGOT, SGPT and alkaline phosphatase values were slightly increased in the first postoperative days, but did not exceed 3-fold of the normal range. CK values were not higher than after surgery per se (1,000 U -') in patients 1, 2 and 3; however, they were increased in patient 4 (3,800 U 1' (Figure 3a) and the costophrenic sulcus and from 0.3 to 0.5 cm at the remaining sites of the cavity, including the lung surface. Even in the presence of full thickness necrosis of the adjacent tumour, underlying structures such as the aorta, nerve ganglion cells and the oesophagus were spared ( Figure  3b and 3c) . However, chondrocytes and osteocytes of the ribs and smooth muscle cells of the aorta adjacent to the destroyed tumour were also altered, due to PDT induced damage of nutritive vessels (Figure 3d ). The lung showed small foci of subpleural alveolitis under the destroyed tumour.
Follow-up No insufficiency of the bronchial stump and no vascular alterations were observed in the remaining three patients during follow-up. Patient 2 showed a diffuse weakness of his right arm without evidence of a lesion of the peripheral nerves, however. CT-scans revealed no structural alterations of the mediastinal organs 3 months after the operation. There was no evidence of disease in patients 2 and 4 on CT-scans at the time, however, patient 1 showed contralateral disease and anterior chest wall invasion at a previous biopsy site.
Discussion
The goal of PDT is selective tumour eradication whilst sparing adjacent normal tissue. A sensitiser with preferential uptake by tumour tissue is administered and activated by a non-thermal dose of laser light of a specific wavelength, leading to free radical formation and destruction of the target tissue. Intraoperative PDT of a tumour bed following surgery is a promising concept for tumours not removable with the required margins of tumour-free tissue. Pilot studies have been done in this respect with HpD and DHE for retroperitoneal sarcomas (Nambisan et al., 1987) , residual or recurrent colorectal cancer in the pelvis (Herrera-Ornelas et al., 1985) , diffuse malignant mesothelioma (Pass et al., 1990; Lofgren et al., 1991) and for disseminated intraperitoneal malignancies (Sindelar et al., 1991) . The results of these studies indicate that large surface PDT is feasible: however, the tumouricidal effect for intraoperative large surface PDT has not been proven in these reports. Moreover, the delivered light dose ranged from 3 to 400 Joules cm-2 and the optimal dose still needs to be clarified. A major hindrance in treating large surfaces is their irregular geometry which renders uniform light delivery difficult. Efficacy and tumour selectivity of PDT are crucial for this purpose. Both depend on the sensitiser used and, according to the given sensitiser, on the interplay of its dose, the light dose and the time interval between application and activation. To overcome the shortcomings of HpD and DHE, new sensitisers have been developed with improved properties in this respect (Pandey et al., 1991) . Among chlorins, mTHPC has shown excellent tumour eradication and tissue selectivity in rodents, requiring only 10 Joules cm-2 to induce tumour necrosis of 0.6 cm depth, and without apparent side effects and minimal skin sensitivity (Berenbaum et al., 1989) . Furthermore, mTHPC strongly absorbs at 650 nm. This wavelength penetrates tissue better than that required for HpD or DHE activation. The effective penetration depth steeply increase in soft tissues between 600 and 650 nm (Wilson & Patterson, 1990) . Our initial clinical results demonstrate a preferential uptake of mTHPC in tumour tissue. The mTHPC concentration was up to 14 times higher in the tumour than in the skin and other normal tissues. In contrast, for HpD and DHE a 2 to 4 ratio of tumour to skin concentration was reported (Gomer & Dougherty, 1979; Moan et al., 1987) . Furthermore, a light dose of 10 Joules cm-2 caused a 10 mm deep tumour necrosis after administration of 0.3 mg kg-mTHPC to our patients. This efficacy has not been reported for DHE-or HpD-PDT. In addition, the only side effect caused by this mTHPC dose was a mild skin sensitivity of shorter duration than observed after HpD or DHE application. Patients have to avoid outdoor sunlight for about 10 days after administration of mTHPC, as opposed to at least 1 month after HpD and DHE application.
As expected from previous results (Nelson et al., 1990) , tumour vessels seem to be the primary target for mTHPC-PDT, leading to necrosis of the vessel wall, thrombosis and subsequent tumour infarction (Figure lb) . However, the different morphology obtained after low light doses ( Figure  2b) 
